HIMS241220C35500
- 0.33
- +0.08+32.00%
Hims & Hers Health Newsroom
Hims & Hers Health Initiated at Overweight by Morgan Stanley
Hims & Hers Health Analyst Ratings
Morgan Stanley Initiates Hims & Hers Health(HIMS.US) With Buy Rating, Announces Target Price $42
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zymeworks (ZYME) and Axsome Therapeutics (AXSM)
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Truist Financial Gives a Hold Rating to Hims & Hers Health (HIMS)
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Hims & Hers Health: Buy Rating Backed by Promising Growth in GLP-1 Market and Strong Telehealth Positioning
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $38
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $38
Hims & Hers Health Analyst Ratings
Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $38
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Citi Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Raises Target Price to $24
Hold Rating on Hims & Hers Health Amidst Regulatory Uncertainty and Market Risks
Hims & Hers Health Analyst Ratings
TD Cowen Reiterates Buy on Hims & Hers Health, Maintains $28 Price Target
TD Cowen Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $28
Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (HIMS) and Celcuity (CELC)